Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma

Gloria S. Huang, Margrit Juretzka, Giuseppe Ciaravino, Sabine Kohler, Nelson N.H. Teng

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Background. Primary adenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established. Case. A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease. Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection. She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions. Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life. She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis. Conclusions. We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma. We observed that Doxil was a well-tolerated and effective agent for this gynecologic malignancy, and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalGynecologic Oncology
Issue number3
StatePublished - Jan 1 2002


  • Adenocarcinoma
  • Doxorubicin
  • Extramammary Paget's disease
  • Liposome
  • Vulvar neoplasm

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma'. Together they form a unique fingerprint.

Cite this